Table 3 Potential genes/pathways related to SALL4 regulation in GIT cancers
From: SALL4 in gastrointestinal tract cancers: upstream and downstream regulatory mechanisms
Gene/Pathway | Aberrant expression in GIT cancer | Function in tumor | Relationship with SALL4 | References |
|---|---|---|---|---|
HOXA11-AS | GC, CRC | Promotes progression | Upregulates SALL4 by sponging miR-3619-5p in NSCLC | Xie et al. (2021); Xia et al. (2021); You et al. (2021); Chen et al. (2020) |
miR-3619-5p | GC, CRC | Suppresses progression | Downregulates SALL4 in NSCLC | |
DNMTs | ESCC, GC, CRC, HCC | Promotes progression | Interacts with SALL4 in HEK293 cell | Fattahi et al. (2018); Yang et al. (2012); Su et al. (2020); Purkait et al. (2022); Luo et al. (2019); Hassouna et al. (2020) |
TP53 | ESCC, GC, HCC | Suppresses progression | SALL4 interacts with p53 and exerts anti-apoptotic function in mouse ESCs | Zhong et al. (2023); Battista et al. (2021); Sahgal et al. (2021); Khemlina et al. (2017); Guichard et al. (2012); Liebl and Hofmann (2021); Wang et al. (2022b) |
MAPK pathway | ESCC, GC, CRC, HCC | Promotes progression | Downstream target of SALL4 in prostate cancer | Fang and Richardson (2005); Shen et al. (2023); Zhang et al. (2020); Yang and Huang (2015); Zheng et al. (2011); Chan et al. (2021); Wang et al. (2022a); Zhou et al. (2023) |